DIRS.INFO The most relevant business & tech news

☆ Here are Friday's biggest analyst calls: Nvidia, Apple, Dell, Netflix, Micron, Broadcom, Eli Lilly, New York Community Bancorp & more
▼ + stars: | 2024-03-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

"We are initiating coverage of Evolent Health with an Outperform rating and $45 price target." Goldman Sachs downgrades Estee Lauder to neutral from buy Goldman downgraded the stock and said it's under "sizeable pressure." "We are upgrading Annexon (ANNX shares) to Overweight from Neutral and establishing a December 2024 price target of $11." Bank of America reiterates Eli Lilly as buy Bank of America raised its price target on the stock to $1000 per share from $800. "Following 4Q23 earnings we are upgrading GoodRx from Neutral to Overweight and increasing our December 2024 price target from $7 to $10."

Persons: Davidson, Campbell, Morgan Stanley, JD, TD Cowen, Parker, Dell, Goldman Sachs, Goldman, Louise Singlehurst, Tom Ford, Jefferies, Root, AVGO's, Stephens, Vita Coco, COCO, Piper downgrades, Piper, Redburn, Oppenheimer, Daiwa, Morgan Stanley downgrades Flywire, Goldman Sachs downgrades Estee Lauder, Estee Lauder, Dwight, Wells, Eli Lilly, Lilly, D.A Organizations: Apple, Vulcan, Merck, Vertex Pharmaceuticals, Bank of America, Broadcom, York Community Bancorp, Netflix, Micron, Mizuho, MU, Citi, EV, Health, Nvidia, Dwight, Hewlett Packard Enterprises, JPMorgan, biosciences, " Bank of America Locations: York, Davidson, Oshkosh, Minneapolis , MN

☆ 'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
▼ + stars: | 2024-02-19 | by ( Michelle Fox | ) www.cnbc.com time to read: +14 min

There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."

Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema

☆ 4 of our stocks report earnings next week. Here's what we want to see from each
▼ + stars: | 2024-02-17 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

A hotter-than-expected consumer price index on Tuesday sent stocks reeling, with the Dow posting its biggest drop in a year. Stocks bounced back over the next two days, helped by a softer retail sales report , only to slump again on Friday's hot producer price index for January. As we said this week, we're not overly concerned with the hotter-than-expected inflationary readings. Earnings season picks back up for the Club next week, with four holdings set to report quarterly results. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Wall, Stocks, we're, Palo, Fortinet, BCH's Bausch, Management doesn't, Dana, Bausch, Dr Pepper, Diana Shipping, Jim Cramer's, Jim Cramer, Jim, Jensen Huang, Walid Berrazeg Organizations: Dow Jones Industrial, Nasdaq, Dow, Federal Reserve, Club, Palo Alto, Palo, billings, Nvidia, Amazon, Microsoft, Bausch Health, Coterra Energy, Management, NYSE, Walmart, Axsome Therapeutics, Barclays Bank, Armstrong World Industries, Ceragon Networks, Tri Pointe Homes, Dana Incorporated, DigitalBridge, Oil States International, Systems, Allegion, CenterPoint Energy, Equitrans Midstream Corporation, Expeditors International of Washington, Alto Networks, SolarEdge Technologies, Enovix Corporation, Caesars Entertainment, Diamondback Energy, Toll, Ternium S.A, Celanese Corp, Chesapeake Energy, CVR Energy, Reserve, Vertiv Holdings Co, Properties Trust, Devices, HSBC Holdings plc, HSBC, Lomb, Sinclair Corporation, Pagaya Technologies, Gibraltar Industries, Garmin, NVIDIA, Rivian Automotive, Sunnova Energy International, Bros, Apache, Oil, Suncor Energy, Co, FNF, Sciences, Coeur D'Alene Mines, Trip.com, Joby Aviation, Resources, Alamos, Jackson, Nutrien, NTR, Pan, Sm Energy Company, Health, Newmont, Nikola Corporation, Cheniere Energy, Fiverr, Natural Resources, Point Credit, Lantheus Holdings, Builders, Grab Holdings, NICE, Dominion Energy, Harmony Biosciences Holdings, Teck Resources Limited, Intellia Therapeutics, Energy, Booking Holdings, Intuit, Semiconductor, Nation Entertainment, Vale S.A, Rocket Companies, Warner Bros ., AerCap Holdings, Natural Holdings, Calumet Specialty Products Partners, Frontier Communications, Jim Cramer's Charitable, CNBC, Lightrocket, Getty Locations: billings, Palo Alto, China, Xifaxan, Tri Pointe, Avista, Gibraltar, Coeur D'Alene, Pan American, Teck, Vale

☆ A former OpenAI exec says AI could be the last technology humans ever invent
▼ + stars: | 2024-01-17 | by ( Katherine Tangalakis-Lippert | ) www.businessinsider.com time to read: +11 min

So now you start compounding the implications on life sciences, and biosciences and it gets really, really exciting. I will say this, I don't think that it is currently popular to espouse an overwhelmingly positive sentiment, because I think it is seen as naive. I think we are so wrapped up in the Terminator Skynet idea, and I just don't think that's even remotely interesting given what we think we're building. I point to nuclear as the best example of how one policy, especially influenced by public perception, can have a really, really incredible consequence on the human experience. I think there is not enough attention paid to the issue of AI versus AI.

Persons: Zack Kass, Kass, Santa Barbara, Sam, Altman, I've, we're Organizations: Artificial Intelligence, biosciences, Artificial General Intelligence Locations: Santa, China

☆ A scientist explains what would happen if all the fish in the ocean disappeared
▼ + stars: | 2024-01-08 | by ( Kory Evans | The Conversation | ) www.businessinsider.com time to read: +5 min

So what would happen to Earth if all the fish in the ocean suddenly disappeared? NOAA, Kevin LinoI'm a scientist who studies fish, their diversity, and all the ways they contribute to ocean environments. Fish as foodFish play important roles as both predators and prey in ocean ecosystems. Related storiesIn coral reef ecosystems, small fish are eaten by larger fish and other marine animals. AdvertisementIn coral reef ecosystems, plant-eating fish control the growth of algae by constantly grazing it down.

Persons: Fish, Kevin Lino I'm, Rogers, parrotfish, Kory Evans Organizations: Service, Fisheries, NOAA, biosciences, Rice University Locations: They're, United States, parrotfish

☆ Stocks making the biggest moves after hours: Box, MongoDB, Dave & Buster's and more
▼ + stars: | 2023-12-05 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Box — The cloud company plummeted 11% after reporting fiscal third-quarter adjusted earnings of 36 cents per share on revenue of $261.5 million. This was lower than FactSet's analyst expectations of 38 cents per share on $262.4 million of revenue. MongoDB — The database stock shed 4% despite MongoDB beating analysts' expectations in its third-quarter earnings. The company's $167 million revenue was also above the forecast $164 million. Dave & Buster's — The stock slipped 3% after the company posted third-quarter revenue of $466.9 million, lower than analysts' forecast for $473 million, per LSEG.

Persons: Asana, Buster's, LSEG Organizations: LSEG, Biosciences, U.S . Food, Drug Administration, crinecerfont, Toll Locations: U.S

☆ These tenbagger stocks are well liked by analysts and may rally even more
▼ + stars: | 2023-12-03 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Over the last 10 years of market turbulence, there haven't been very many stocks that have seen a more than 1,000% compound return. Fewer still of these "tenbaggers," companies that have multiplied in value 10 times, have sizeable upside expectations ahead. The average analyst still sees potential upside of 40%. Early last month, Jefferies began research coverage of Celsius with a buy rating, citing several growth opportunities that lie ahead. With a 10-year compound total return of nearly 13,000%, chipmaker Nvidia was also at the top of the list.

Persons: Jefferies, Kaumil Gajrawala, Fred Imbert Organizations: CNBC, Holdings, PepsiCo, Nvidia, Microsoft, Semiconductor, Broadcom, Builders, Neurocrine Biosciences Locations: Florida

☆ Not so dead as a dodo: ‘De-extinction’ plan to reintroduce bird to Mauritius
▼ + stars: | 2023-12-01 | by ( Tom Page | ) edition.cnn.com time to read: +10 min

CNN —An audacious collaboration between geneticists and conservationists plans to bring back the extinct dodo and reintroduce it to its once-native habitat in Mauritius. But according to the partners, its return to Mauritius could benefit the dodo’s immediate environment and other species. The Nicobar pigeon, native to the coastal regions from the Andaman and Nicobar Islands, is the closest living relative to the dodo. Then it will edit the PGCs of a Nicobar so it expresses the physical traits of a dodo. “I have studied the dodo for many years, and there is still a lot to learn about this enigmatic bird,” he added.

Persons: dodo, Beth Shapiro, ”, Matt James, James, Holger Hollemann, Tatayah, ” Tatayah, “, dodos, Ben Birchall, Julian Hume, ” Hume, Ben Lamm, “ We’re Organizations: CNN, Colossal Biosciences, Mauritian Wildlife Foundation, Getty, Gorges, Colossal, “, White Rhino, Biosciences Locations: Mauritius, Rodrigues Island, Asia, Nicobar, Park, “ Mauritius, Aigrettes, Ile

☆ Stocks making the biggest moves before the bell: Alibaba, Applied Materials, Gap and more
▼ + stars: | 2023-11-17 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

Check out the companies making headlines in premarket trading. BJ's Wholesale Club — Shares retreated 4.6% in premarket trading after the company revised its expectation for comparable store sales in the fourth quarter amid shifting consumer behavior. Applied Materials — Shares slid 7.2% on Friday, a day after Reuters reported , citing sources, that the semiconductor company was under a Justice Department probe. Gap — The retailer soared 18.5% in premarket trading Friday. Marriott Vacations Worldwide — Shares of the timeshare company lost 2.5% after a Bank of America downgrade to underperform from neutral.

Persons: Alibaba, FactSet, Ross, Expedia, Morgan Stanley, — CNBC's Hakyung Kim, Sarah Min Organizations: BJ's Wholesale, Tenet Healthcare, Novant Health, Reuters, Justice Department, Ross, LSEG, Evercore ISI, Pacific Biosciences, UBS, biosciences, Barclays, Marriott, Bank of America Locations: Alibaba —, Carolina, California, GitLab

☆ Here are Friday's biggest analyst calls: Nvidia, Zoom, Expedia, Analog Devices, Cava, Roblox, Dick's & more
▼ + stars: | 2023-11-17 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Roth MKM downgrades ChargePoint to neutral from buy Roth said it's concerned about weak demand for charging equipment. UBS upgrades Pacific Biosciences to buy from neutral UBS said the biotech company has growth potential. Citi reiterates Microsoft as buy Citi said it's standing by its buy rating on the stock. Morgan Stanley upgrades Analog Devices to overweight from equal weight Morgan Stanley said the bottom is in sight for the semiconductor company. Truist initiates Dick's as buy Truist said in its initiation of the stock that it sees an attractive buying opportunity. "

Persons: Evercore, Roth, it's, CHPT, Wolfe, underperform Wolfe, RBLX, GitLab, Hubbell, Morgan Stanley, Carvana, Raymond James, Cava, Redburn, Piper Sandler, Piper, buybacks, Baird, Truist, Lululemon, Kimberly, Clark Organizations: EV, UBS, Pacific Biosciences, Citi, Microsoft, Barclays, JPMorgan, HSBC, UW, downgrades, Products, Nvidia, Coherus BioSciences, Goods, Zim Locations: ChargePoint, billings, 2Q24

☆ Stocks making the biggest moves midday: Gap, Ross Stores, Tenet Healthcare and more
▼ + stars: | 2023-11-17 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

Adjusted earnings of 59 cents per share smashed analysts' expectations of 19 cents per share, per LSEG. Revenue also beat estimates, coming in at $3.77 billion compared with the $3.6 billion forecast. Otherwise, the company topped fiscal fourth-quarter earnings and revenue estimates. It now forecasts third-quarter revenue of $108 million to $113 million, lower than prior guidance of $150 million to $165 million. Tenet Healthcare — Shares jumped more than 11% after Tenet Healthcare said it would sell three of its South Carolina hospitals to Novant Health.

Persons: Ross, Dillard's, GitLab, — CNBC's Brian Evans, Alex Harring, Hakyung Kim, Tanaya Macheel, Pia Singh Organizations: Old Navy, Revenue, Brands Holdings, Spectrum Brands, ChargePoint Holdings, Tenet, Tenet Healthcare, Novant Health, Ross Stores, Reuters, Justice Department, Pacific Biosciences, UBS, biosciences, —, ISI, Barclays Locations: South Carolina, California

The company's research and development (R&D) engine is intact and therefore it is unlikely to do transformative deals soon, Jorgensen said. It was the latest in a series of similarly-sized deals the company has done this year. Last week, when reporting quarterly earnings, it forecast another year of double-digit sales growth for its two most popular drugs: weight-loss drug Wegovy and diabetes Ozempic. To keep up with demand, Novo is racing to increase production of those drugs, which contain the same active pharmaceutical ingredient, semaglutide, and are delivered in self-injection pens. A healthcare banker, speaking on condition of anonymity, told Reuters after the interview there were many companies in the cardiometabolic space with early-stage drugs that Novo Nordisk may be able to buy.

Persons: Lars Fruergaard Jorgensen, Wegovy, Jorgensen, Novo, Novo's, Jacob Gronholt, Maggie Fick, Terje Solsvik, Emelia, Barbara Lewis Organizations: Novo, Novo Nordisk, Reuters, KBP Biosciences, Nordisk, Pedersen, Thomson Locations: Novo, COPENHAGEN, Singapore, Copenhagen, London

As the company's fortunes soar on demand for its popular weight-loss medicine Wegovy, Jorgensen said Novo sought to acquire companies working on medicines in the areas where it is already focused. The company's research and development (R&D) engine is intact and therefore it is unlikely to do transformative deals soon, Jorgensen said. It was the latest in a series of similarly-sized deals the company has done this year. Last week, when reporting quarterly earnings, it forecast another year of double-digit sales growth for its two most popular drugs: weight-loss drug Wegovy and diabetes Ozempic. To keep up with demand, Novo is racing to increase production of those drugs, which contain the same active pharmaceutical ingredient, semaglutide, and are delivered in self-injection pens.

☆ What If Men Could Make Their Own Egg Cells?
▼ + stars: | 2023-10-27 | by ( Amy Dockser Marcus | ) www.wsj.com time to read: 1 min

The Japanese biologist Katsuhiko Hayashi said earlier this year that he believes it will be possible to create a human egg from skin cells within a decade. He and his colleagues have already turned skin cells from male mice into mouse eggs and used them to breed baby mice. Matt Krisiloff , chief executive officer of Conception Biosciences, has dozens of scientists working at a lab in Berkeley, Calif., trying to make eggs outside ovaries. Such a technique could allow women to have biological children later in life.

Persons: Katsuhiko Hayashi, Matt Krisiloff Organizations: Conception Biosciences Locations: Berkeley, Calif

☆ Merck results beat expectations on strong Keytruda sales, surprise Covid drug growth
▼ + stars: | 2023-10-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations on strong sales of its blockbuster cancer drug Keytruda, HPV vaccine Gardasil and surprisingly, its Covid drug Lagevrio. Merck lowered its adjusted profit guidance to $1.33 to $1.38 per share, from a previous forecast of $2.95 to $3.05 a share. But that updated outlook reflects an upfront charge of $5.5 billion, or $1.70 per share, related to the company's recent drug collaboration agreement with Daiichi Sankyo. Excluding Lagevrio, pharmaceutical sales grew 9%. The Covid antiviral treatment brought in $640 million in sales for the quarter, up 47% from the third quarter of 2022.

Persons: Merck Organizations: Merck, Prometheus Biosciences, Imago BioSciences, Kelun, Biotech, LSEG, U.S Locations: Japan, Australia

☆ A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free
▼ + stars: | 2023-10-24 | by ( Filip De Mott | ) www.businessinsider.com time to read: +4 min

Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. AdvertisementAdvertisementRoche's acquisition of a bowel-inflammation treatment delivered a massive windfall for presidential candidate Vivek Ramaswamy's company Roivant, the Wall Street Journal reported. But Roivant's expenses to develop the treatment, which targets an inflammatory protein called TL1A, amounted to just $15 million. And just this month, a $1.5 billion collaboration between Sanofi and Teva Pharmaceuticals was announced for more TL1A treatment. "This is a $15 billion market just in the US, and that's just in [inflammatory bowel disease," Roche chief Teresa Graham told the Journal.

Persons: Roche, Roivant, —, Vivek Ramaswamy's, Pfizer, TL1a, that's, " Roche, Teresa Graham Organizations: Wall Street Journal, Pfizer, Service, Telavant Holdings, Food and Drug Administration, Roivant, Prometheus Biosciences, Merck, Sanofi, Teva Pharmaceuticals, pharma Locations: Roivant, Japan

☆ Roche's $7 bln deal is pricey and partial cure
▼ + stars: | 2023-10-23 | by ( ) www.reuters.com time to read: +2 min

Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot January 22, 2016. REUTERS/Dado Ruvic/Illustration Acquire Licensing RightsNEW YORK, Oct 23 (Reuters Breakingviews) - Roche (ROG.S) has taken a small step towards curing its drug pipeline problem. JPMorgan analysts estimate that the drug’s U.S. sales could peak at 2.4 billion Swiss francs ($2.7 billion), but will take until 2037 to get there, assuming a 2028 launch. Analysts expect Roche’s pharmaceutical division to generate revenue of almost 45 billion Swiss francs this year, according to estimates compiled by LSEG. With expected free cash flow of around 16 billion Swiss francs this year and next, Roche can afford to buy a little more diversification.

Persons: Roche, Dado Ruvic, Thomas Schinecker, Peter Thal Larsen, Jean, Pierre Mustier, Atos, Jonathan Guilford, Aditya Sriwatsav Organizations: REUTERS, Reuters, Pfizer, U.S, New, JPMorgan, Merck, Prometheus Biosciences, Analysts, LSEG, X, News Corp, Thomson Locations: Swiss, U.S

New Roche CEO Thomas Schinecker is keen to restore Roche's battered drug development record after major late-stage trial setbacks in the areas of Alzheimer's and cancer immunotherapy last year. The acquired drug, against inflammatory bowel disease such as ulcerative colitis and Crohn's disease, belongs to a class of new treatments known as anti-TL1A antibodies which has attracted major deal activity in the pharma industry. Merck & Co (MRK.N) in April agreed to buy anti-TL1A antibody developer Prometheus Biosciences for $10.8 billion. Inflammatory bowel disease is a group of chronic gastrointestinal disorders with almost 8 million people diagnosed worldwide and 80% of all individuals not experiencing lasting remission, Roche said. "We strongly believe this novel TL1A directed antibody has the transformational potential to make a significant difference for patients living with inflammatory bowel disease and potentially other diseases," said Roche CEO Schinecker.

Persons: drugmaker Roche, Arnd, New Roche, Thomas Schinecker, Schinecker, Roche, John Revill, Ludwig Burger, Friederike Heine, Jason Neely Organizations: REUTERS, Roivant Holdings, Pfizer Inc, pharma, Sanofi, Merck & Co, Prometheus Biosciences, Thomson Locations: Basel, Switzerland, ZURICH, FRANKFURT, Swiss, U.S, Japan, Zurich, Frankfurt

☆ Novo Nordisk in $1.3 bln deal to buy hypertension drug
▼ + stars: | 2023-10-16 | by ( ) www.reuters.com time to read: +1 min

Flags with the Novo Nordisk logo flutter outside their Danish company's offices in Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo Acquire Licensing RightsCOPENHAGEN, Oct 16 (Reuters) - Novo Nordisk (NOVOb.CO) has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion, the Danish drugmaker said on Monday. "This deal is closely aligned with our strategic focus on expanding from our core in diabetes into other serious chronic diseases, including through novel drug modalities," Novo said in a statement. The acquisition is expected to close before the end of this year, Novo said, adding that the deal will not impact its operating profit outlook for 2023. Ocedurenone is an orally administered drug that is currently examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease, Novo said.

Persons: Tom Little, Danish drugmaker, Novo, Louise Breusch Rasmussen, Terje Solsvik Organizations: Novo Nordisk, Danish, REUTERS, Rights, KBP Biosciences, CLARION, Thomson Locations: Copenhagen, Denmark, Rights COPENHAGEN, Danish

The two Africa-based vaccine manufacturers are receiving $5 million each in funding from the foundation, while another $10 million is earmarked for other companies that have not yet been named. Political Cartoons View All 1202 ImagesThe mRNA vaccine technology came to the forefront with the production of COVID-19 vaccines made by Pfizer and Moderna. Those COVID-19 mRNA vaccines were fast-tracked through the regulatory process and granted emergency use authorization. The new vaccines under development in Africa face a far longer development timeline — anywhere from three to seven years. It has spent billions of dollars to vaccinate against polio, treat and prevent malaria and HIV and more recently advance vaccines for diseases like cholera.

Persons: Melinda Gates, Bill Gates, “, Dr, Amadou Sall, ” Sall, COVID, ” Jose Castillo, ___ Mark Carlson Organizations: Melinda Gates Foundation, Associated Press, Institut Pasteur, Quantoom Biosciences, Pfizer, Moderna, Gates Foundation Locations: DAKAR, Senegal, Africa, Dakar, South Africa, Belgium, Crimean, Congo, Nivelles

☆ Here are Wednesday's biggest analyst calls: Tesla, Apple, Microsoft, Mattel, Amazon, Costco & more
▼ + stars: | 2023-09-27 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

UBS reiterates Apple as neutral UBS said its survey checks show wait times for Apple's newest iPhone are shorter than compared to one year ago. Deutsche Bank reiterates Tesla as buy Deutsche said it sees "meaningful downside risk" in 2024 for Tesla, but that it's standing by its buy rating. " Bank of America reiterates Costco as buy Bank of America said it's standing by its buy rating after the company's earnings report Tuesday. "We initiate coverage of Leonardo DRS with a Buy rating and a $20 price objective, implying 23% upside potential." Bank of America reiterates Walmart as buy Bank of America said it sees gross margin expansion continuing for shares of the big box retailer.

Persons: Tesla, Goldman Sachs, Goldman, Brent, Morgan Stanley, Leonardo, Mattel, Evercore, TD Cowen, Levi's, William Blair, Berenberg, DA Davidson Organizations: Street, HSBC, Johnson, UBS, Apple, Deutsche Bank, Deutsche, Chevron, Bank of America, Occidental Petroleum, Costco, Kosmos Energy, of America, T Bank, MTB, Amazon, Electric Vehicle Supply, Leonardo DRS, BMO, Microsoft, Mattel, Biosciences, Twist Bioscience Corp, Walmart Locations: China, Europe, Berkshire

☆ It's not just the uber-rich freezing their brains and bodies when they die. An HBO show visited a conference filled with everyday people excited to do it.
▼ + stars: | 2023-09-24 | by ( Kylie Kirschner | ) www.businessinsider.com time to read: +5 min

The series finale of HBO's "How To with John Wilson" explored cryonics and the quest for immortality. Sam Altman, Jeff Bezos, Peter Thiel, and Bryan Johnson all invested in anti-aging or cryonics. Get the inside scoop on today’s biggest stories in business, from Wall Street to Silicon Valley — delivered daily. Insider has previously reported on Alcor competitor Cryonics Institute, a more affordable alternative that charges $28,000 for a body to be stored indefinitely. A Cryonics Institute model of the tanks used to store bodies, which are actually stored upside down in practice.

Persons: John Wilson, Sam Altman, Jeff Bezos, Peter Thiel, Bryan Johnson, It's, Wilson, hasn't, Bari Weiss, he's, Johnson Organizations: Service, Alcor, HBO, MIT Technology, Biosciences, Altos Labs Locations: Wall, Silicon, Altos

☆ Acelyrin's skin disease drug trial failure wipes off IPO gains
▼ + stars: | 2023-09-12 | by ( Christy Santhosh | ) www.reuters.com time to read: +2 min

Sept 12 (Reuters) - Shares of drug developer Acelyrin (SLRN.O) on Tuesday erased all gains made since their stellar market debut in May, as the company's experimental lead drug failed to show superiority to placebo in reducing symptoms of an inflammatory skin disease. HS is a chronic inflammatory skin condition that causes painful lumps under the skin. Acelyrin said the trial was hit by early discontinuations as well as better placebo efficacy rates. However, Jefferies analyst Akash Tewari slashed the price target on Acelyrin's stock to $15 from $31, calling the latest data "painfully disappointing." "It's difficult to glean much from the data given how poorly the trial was run.

Persons: Acelyrin, Acelyrin's izokibep, Hidradenitis, Piper Sandler, Jefferies, Akash Tewari, We'll, Christy Santhosh, Saumyadeb Chakrabarty Organizations: Ventyx Biosciences, Apogee Therapeutics, Thomson Locations: Acelyrin, Bengaluru

LONDON (AP) — Ian Wilmut, the cloning pioneer whose work was critical to the creation of Dolly the Sheep in 1996, has died at age 79. While Dolly's creation was heralded as a revolution by some scientists, it unnerved many, with critics calling such experiments unethical. Wilmut, a trained embryologist, later focused on using cloning techniques to make stem cells that could be used in regenerative medicine. Whitelaw described Wilmut as a “titan” of science and said his work in Dolly's creation transformed scientific thinking at the time. He said the legacy of Wilmut's work in cloning Dolly continues to be seen.

Persons: Ian Wilmut, Dolly, Wilmut, Dolly Parton, Bill Clinton, Sir Ian Wilmut, Bruce Whitelaw, Whitelaw, ” Organizations: University of Edinburgh, biosciences, Roslin Locations: Scotland

☆ Sam Altman thinks Silicon Valley has lost its culture of innovation
▼ + stars: | 2023-09-07 | by ( Kai Xiang Teo | ) www.businessinsider.com time to read: +3 min

OpenAI's Sam Altman thinks Silicon Valley no longer has an innovation culture. "Before OpenAI, what was the last really great scientific breakthrough that came out of a Silicon Valley company?" Get the inside scoop on today’s biggest stories in business, from Wall Street to Silicon Valley — delivered daily. "There used to be great research that happened in companies in Silicon Valley, Xerox PARC being the obvious example. To this, Altman responded by saying Silicon Valley did have a product innovation culture, but he felt it missed the mark on groundbreaking research.

Persons: OpenAI's Sam Altman, Sam Altman, Altman, Nicolai Tangen, I'm, Marc Andreessen, Andreessen, Horowitz, Matt Miller, Altman's OpenAI, ChatGPT, OpenAI Organizations: Service, Xerox PARC, Norges Bank Investment, Sequoia Capital, Biosciences Locations: Wall, Silicon, Silicon Valley, China, California, OpenAI

Search resuls for: "BioSciences"

25 mentions found